| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
10,111 |
9,354 |
$760K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
2,895 |
2,689 |
$415K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
1,285 |
1,176 |
$148K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
3,307 |
2,960 |
$109K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
580 |
544 |
$105K |
| G0378 |
Hospital observation service, per hour |
495 |
367 |
$100K |
| 80053 |
Comprehensive metabolic panel |
9,051 |
6,917 |
$88K |
| 70450 |
Computed tomography, head or brain; without contrast material |
1,257 |
1,159 |
$77K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
1,786 |
1,660 |
$69K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
11,393 |
8,138 |
$67K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
1,703 |
1,601 |
$66K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
2,100 |
1,931 |
$63K |
| 71045 |
Radiologic examination, chest; single view |
3,628 |
3,226 |
$63K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
1,178 |
1,053 |
$58K |
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
1,300 |
1,234 |
$57K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
464 |
434 |
$53K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
1,848 |
1,677 |
$36K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
239 |
219 |
$34K |
| 80050 |
General health panel |
321 |
297 |
$32K |
| 83880 |
|
1,446 |
1,304 |
$23K |
| 84484 |
|
3,219 |
2,272 |
$17K |
| 84703 |
|
2,363 |
2,089 |
$16K |
| 80143 |
|
818 |
721 |
$14K |
| 81001 |
|
3,633 |
3,335 |
$13K |
| 80179 |
|
810 |
718 |
$12K |
| 83690 |
|
2,215 |
2,009 |
$9K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
608 |
575 |
$9K |
| 80320 |
|
738 |
651 |
$9K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
405 |
376 |
$8K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
1,557 |
1,175 |
$8K |
| 87430 |
|
350 |
331 |
$7K |
| 76801 |
|
84 |
78 |
$7K |
| 71046 |
Radiologic examination, chest; 2 views |
237 |
223 |
$7K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
946 |
696 |
$7K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
1,054 |
984 |
$6K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
248 |
96 |
$6K |
| 83735 |
|
2,363 |
1,666 |
$6K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
958 |
868 |
$5K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
126 |
116 |
$5K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
2,828 |
2,552 |
$4K |
| 85610 |
|
1,993 |
1,557 |
$3K |
| 83605 |
|
808 |
636 |
$3K |
| 86850 |
|
370 |
330 |
$3K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
102 |
97 |
$3K |
| 84702 |
|
196 |
173 |
$3K |
| 85730 |
|
1,253 |
1,134 |
$3K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
103 |
98 |
$2K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
31 |
29 |
$2K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
1,408 |
1,301 |
$2K |
| 87807 |
|
66 |
64 |
$2K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
66 |
63 |
$2K |
| 86769 |
|
90 |
83 |
$2K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
2,128 |
1,760 |
$2K |
| 81003 |
|
1,111 |
1,039 |
$2K |
| 86900 |
|
977 |
739 |
$1K |
| 86901 |
|
973 |
738 |
$1K |
| 84145 |
|
212 |
189 |
$1K |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
1,354 |
1,009 |
$1K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
17 |
14 |
$1K |
| 85379 |
|
204 |
192 |
$1K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
1,079 |
984 |
$917.38 |
| 87040 |
|
195 |
96 |
$742.71 |
| 84100 |
|
595 |
439 |
$699.95 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
895 |
796 |
$658.94 |
| 87081 |
|
78 |
74 |
$627.28 |
| 82728 |
|
163 |
152 |
$626.80 |
| 87186 |
|
129 |
118 |
$604.52 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
1,963 |
1,679 |
$363.92 |
| 83036 |
Hemoglobin; glycosylated (A1C) |
106 |
96 |
$358.80 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
643 |
557 |
$280.54 |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
16 |
13 |
$274.14 |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
150 |
142 |
$271.00 |
| 87077 |
|
40 |
39 |
$237.79 |
| 86140 |
|
71 |
66 |
$216.34 |
| 83615 |
|
98 |
94 |
$196.72 |
| 87088 |
|
26 |
26 |
$173.85 |
| J1650 |
Injection, enoxaparin sodium, 10 mg |
23 |
13 |
$87.74 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
173 |
138 |
$71.58 |
| 82962 |
|
4,349 |
1,181 |
$58.10 |
| J2060 |
Injection, lorazepam, 2 mg |
95 |
83 |
$53.53 |
| J0360 |
Injection, hydralazine hcl, up to 20 mg |
34 |
28 |
$24.25 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
62 |
55 |
$17.70 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
15 |
12 |
$2.07 |
| J8499 |
Prescription drug, oral, non chemotherapeutic, nos |
2,899 |
851 |
$0.76 |
| J3490 |
Unclassified drugs |
128 |
94 |
$0.00 |
| 36415 |
Collection of venous blood by venipuncture |
69 |
66 |
$0.00 |
| J1642 |
Injection, heparin sodium, (heparin lock flush), per 10 units |
39 |
24 |
$0.00 |
| 96376 |
|
15 |
14 |
$0.00 |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
12 |
12 |
$0.00 |